Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus met® XR in Subjects with Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment

Grant

Date/time Interval

  • September 9, 2016 - November 1, 2020
  • Total Award Amount

  • 10618.00
  • Direct Costs

  • 7150.00
  • Sponsor Award Id

  • 0000000660
  • Contributor

  • Yedeh Ying M.D.   Principal Investigator